Using Strength Tests to Better Understand How Pancreatic Cancer Affects Muscle Mass and Quality of Life (NCT07255001)
Monitoring Physical Function Changes in Patients With Pancreatic Ductal Adenocarcinoma: Potential for Better Understanding of Treatment Trajectory and Survival
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to measure hand grip strength in adults with pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: * Is it feasible to measure hand grip strength as part of a clinic visit? * Are changes in hand grip strength related to changes in body composition? * Is hand grip strength related to a person's well-being? * Is hand grip strength related to how a tumour responds to treatment? Participants will squeeze a device with their hand to measure their hand grip strength and complete questionnaires about their well-being when they are seen in clinic for their regular medical care for PDAC.
Who can join: Review the eligibility criteria below.
Location: BC Cancer — Vancouver, British Columbia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- BC Cancer — Vancouver, British Columbia
📞 Contact the Study Coordinator
Phone: (800) 663-3333
Email: drenouf@bccancer.bc.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pancreatic Ductal Adenocarcinoma (PDAC)
- Reach and Engagement of GENetic Education, Risk Assessment, and TEsting Feasibility Trial — Boston, Massachusetts
- PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) — Burlington, Vermont
- ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) — Birmingham, Alabama
- Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer — La Jolla, California
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer — Los Angeles, California
Explore by condition: All Pancreatic Ductal Adenocarcinoma (PDAC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.